Introduction
About 6-10% of all newly diagnosed primary brain tumors in adults are considered to be WHO grade III tumors or anaplastic gliomas: anaplastic astrocytoma, anaplastic oligoastrocytoma (AOA) or anaplastic oligodendroglioma. After three randomized phase III trials [1, 2, 3 ], the standard of care for all anaplastic gliomas is to use postoperative radiotherapy or chemotherapy alone, despite the frequent common practice to embark on regimens developed for the treatment of glioblastoma [4] [5] [6] . A part of this discrepancy between science and daily practice is explained by the diagnostic uncertainties that are associated both with typing and grading of gliomas as well as the obvious room for improvement in glioma therapy. Enriching patient populations with comparable prognosis via easier and more objectively defined or at least complementary molecular parameters, such as deletions of 1p/19q, hypermethylation of CpG residues in the promotor of the O 6 -methyl-guanyl-methyl-transferase (MGMT) gene or mutations in codon 132 of the isocitrate dehydrogenase (IDH) 1 gene, might help to differentiate between those who need maximal primary treatments and those who do better regardless of treatments with (late) side effects as one major concern.
Review
This review focuses on the current clinical standard after four randomized trials in the past years, the important molecular translational data and the critical questions for further diagnostic, clinical and translational development.
Clinical situation
The common practice of care for anaplastic astrocytoma is to use postoperative radiotherapy alone or to embark on regimens developed for the treatment of malignant gliomas in general [4] [5] [6] . The prognostic impact of the surgical resection remains a field of controversy because of the scarcity of prospective clinical data. Although not uniformly assessed by early postoperative imaging as in the 5-aminolevulinic acid (ALA) trial for glioblastoma [7] , Purpose of review To summarize findings, discuss problems and define new questions from the past phase III trials in anaplastic gliomas.
Recent findings
The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy. The next steps are to define the role and optimal sequencing of combined modality treatment focusing on radiotherapy and temozolomide and to develop trials with novel targeted treatments. The feature of necrosis in oligodendroglial tumors needs to be further studied, and molecular prognosticators will take more room. These include O 6 -methylguanylmethyltransferase promoter methylation, isocitrate dehydrogenase mutations and epidermal growth factor receptor amplification. Further, the notion that all anaplastic oligodendroglial tumors with or without a relevant astrocytic component fall into the same prognostic category and the obvious difficulties to type and to grade anaplastic gliomas pose an enormous burden on local diagnosis. The current and upcoming trials including the European Organization for Research and Treatment of Cancer 26053/22054 trial aim at solving some of these issues with an initial central pathology review. Summary Anaplastic gliomas are an important group of brain tumors to develop future molecularly targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at efficacy and avoiding long-term side effects.
but as judged by the neurosurgeon, analysis of surgical data from the Neuroonkologische Arbeitsgemeinschaft-04 (NOA-04) trial makes a strong point for the prognostic value of a gross total resection [3 ] .
The standard of care in oligodendroglial tumors is biased by the conclusions that have been drawn from the landmark work of Cairncross and colleagues [8] introducing procarbazine, lomustine and vincristine (PCV) chemotherapy as well as 1p/19q deletions as a molecular marker into the treatment of these tumors with the notion that sensitivity towards chemotherapy and not -as discovered later -towards any therapy is the reason for relative success of treating these tumors. Consequently, all large trials in the past years have also focused on PCV.
In contrast to glioblastoma [9] and a German trial [5] , it was felt that sequential radiotherapy and chemotherapy, but not the immediate combination of both, would improve outcome. A phase III trial including all subtypes of anaplastic gliomas conducted by the Neurooncology Working Group (NOA) of the German Cancer Society (NOA-04 trial) was designed to study sequencing of therapies by comparing efficacy and safety of radiotherapy versus chemotherapy (temozolomide or PCV) and using the remaining therapy at progression. Primary therapy with radiation or with chemotherapy and subsequent salvage treatment with the other modality elicited comparable therapeutic results, and there was no difference in the outcome between pure anaplastic oligodendroglioma and mixed AOA; however, tumors with an oligo component had a significantly more favorable survival as compared with anaplastic astrocytoma [3 ] . Overall, the median survival was in the range of 7 years, stressing the importance for long-term follow-up and attention to long-term (neuro)toxicity [10 ] .
Dilemma in diagnostic neuropathology
Areas of major subjectivity in diagnostic neuropathology that are not clearly regulated in the current WHO classification are the differentiation between grade II and III astrocytoma, the classification of oligodendroglial tumors with necrosis and the diagnosis of a mixed glioma, that is, an oligoastrocytoma.
Difficulties in typing and grading
The revised 2007 WHO classification of brain tumors no longer accepts the diagnosis of 'mixed AOA'; if necrosis is present, these tumors should be considered glioblastomas (perhaps with oligodendroglial features). The EORTC 26951 trial supports this notion; in addition, the feature of necrosis is prognostic in the pure oligodendroglial tumors allowing four groups (anaplastic oligodendroglioma with or without necrosis and AOA with or without necrosis) [11 ] ; however, up to one-third of patients included in this trial were considered glioblastoma on central pathology review. This also contrasts NOA-04 trial in which no prognostic difference between anaplastic oligodendroglioma and AOA was found. Thus, relevance of necrosis in pure oligoastrocytoma needs to be revisited and slides from the NOA-04 trial re-analyzed. Classification onto a higher grade, that is, from II to III, is mainly reached by comparably higher cellularity, nuclear atypia and mitotic activity and a more marked pleomorphism. A threshold for the diagnosis of a mixed anaplastic glioma is missing. These data are leading to the following scenario.
Interobserver variability
A set of 114 tumors from EORTC 26951 trial was reviewed independently by nine internationally renowned pathologists: P. Collins, D. Figarella-Branger, C. Giannini, F. Giangasparo, M.J. Kros, K. Mokhtari, S.J. Mork, A. Paetau and G. Reifenberger. In this set of anaplastic oligodendroglial tumors according to study entry criteria, the panel diagnosed a low-grade glioma in 1-16%, an anaplastic astroycytoma in up to 11% and a glioblastoma in 1-27% [12] . A similar exercise was done on the material from the RTOG 94-02 trial that had a central review to begin with to differentiate classical from nonclassical oligodendroglial histologies. Because of soft criteria, interobserver variability was again high [13 ] . In addition to other confounding factors at study entry such as timing, inclusion criteria, time to diagnosis and the decision to treat and the caveats of comparing trials, this intrinsic typing and grading variability leads to major differences in outcome parameters when EORTC 26951, RTOG 94-02 and NOA-04 trials are compared (Table 1) .
Guidance on when to use local and central pathology review although previous data indicated a less favorable prognosis for AOA patients [14] . Not only the discrepancy between local diagnoses and central review in up to 40% of cases but also the high rate of disagreement among central review expert neuropathologist raises doubts on the reproducibility of the diagnostic criteria. In the NOA-04 trial, we used a rather restrictive histological AOA definition and classified astrocytic tumors with just minute or ambiguous oligodendroglial differentiation features into the anaplastic astrocytoma group. This approach separated two prognostically distinct anaplastic glioma groups: anaplastic astrocytoma versus anaplastic oligodendroglioma and AOA. We argue that tumors with an unequivocal and quantitatively significant oligodendroglial component, in addition to astrocytic tumor parts, should qualify for a mixed oligoastrocytic glioma diagnosis; this may help to constrain the relative increase in oligodendroglial tumor diagnoses in recent years [15] . Although in the EORTC 26951 trial patient inclusion was based on a local diagnosis, the trial may at the end have been underpowered to detect a difference in the eligible patients. In contrast, in the German and North American trial, a pathology review was required before randomization. Similarly, in the ongoing EORTC-Intergroup Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma (CATNON) trial, pathological review and molecular markers are to be performed centrally before randomization.
Consideration has to be given as to how results of trials with central histopathology are translated into daily clinical practice outside clinical trials. In this case, treatment decisions will be based on local histopathology. Emphasis should be put on introducing molecular markers to the WHO classification to reduce the subjective elements of diagnosis.
What is the role of imaging?
Before the pathological entry criteria are unified, tackling imaging questions may seem premature. However, closer correlations between histology and MRI parameters, such as perfusion-weighted imaging or magnetic resonance (MR) spectroscopy [16 ] or PET [17 ] , might add to the decision of typing and grading in anaplastic tumors. Further, pooling of imaging data to work on growth and recurrence patterns [18 ] is warranted. Larger, collaborative approaches with standardized imaging protocols such as the German Glioma Network (www.gliomnetzwerk.de) will be necessary to substantiate the initial findings.
Molecular markers
Attempts have been made to correlate clinical outcome with specific predictive markers in the tumor tissue, including genetic deletions, particularly combined deletion of chromosomal arms 1p and 19q [8] , hypermethylation/gene silencing of specific promoters, notably the MGMT gene promoter in glioblastomas [19] or gene amplification, particularly in growth factor receptors and cell cycle regulatory events [20] .
Classical 1p/19q
Deletion of 1p and 19q predicts a superior outcome in anaplastic glioma patients treated with radiotherapy or chemotherapy [3 ,8] but not in patients with low-grade oligodendroglial tumors treated with surgery alone [21] . In a correlative study to EORTC 26951 trial, the 1p/19q codeletion was mainly diagnosed in anaplastic oligodendroglioma, associated with growth in the frontal lobe, and was the strongest positive prognostic marker retaining relevance also in the multivariate analysis [11 ] , which, however, did not include MGMT and IDH1. Today, 1p/ 19q deletions are understood to occur by an unbalanced translocation of 19p to 1q t(1;19)(q10;p10) [22, 23] , prognostic in both anaplastic astrocytoma and anaplastic oligodendroglioma/AOA for either radiotherapy or chemotherapy and not predictive for a therapy modality and useful for entry into a clinical trial (EORTC 26053-22054/Intergroup CATNON at www.eortc.be).
The two-headed O 6 -methyl-guanyl-methyl-transferase: outlook to solve the problem MGMT is a ubiquitous DNA repair enzyme, which is associated with resistance to alkylating agent cancer therapy [24] . The MGMT gene promoter methylation status determined by methylation-specific PCR (MSP) is the strongest prognostic factor for outcome of newly diagnosed glioblastoma patients and a powerful predictor of response to alkylating chemotherapy [19,25 ,26,27, 28 ]. There is a strong correlation between response to temozolomide and the MGMT promoter methylation status. Patients with a methylated MGMT promoter appear to benefit from the addition of temozolomide, whereas those whose tumor does not have a methylated MGMT promoter had a significantly worse survival and less benefit from the addition of temozolomide to radiotherapy (OS rate at 24 months: 14 versus <2%) [19] . This raises the question whether the small benefit from chemoirradiation observed in this group outweighs the toxicity and costs of the temozolomide treatment and calls for the development of more effective drug regimens for this specific group of patients. Although there may be a few patients with an unmethylated MGMT promoter who do derive benefit from combined temozolomide and irradiation, and despite limitations and controversy about the best technique for determination of MGMT status, the overall benefit for the entire subgroup of these molecularly characterized subgroup is marginal at best. One attempt to answer this question has led to the development of trials according to MGMT status with intensification of temozolomide-containing radiochemotherapy for patients with methylated MGMT promoter and replacement of the alkylating agent (temozolomide) by non-MGMT substrates that may synergistically act with radiotherapy such as enzastaurin [29, 30 ] or temsirolimus (www.eortc.be).
Interestingly, the NOA-04 anaplastic glioma trial showed no difference in PFS or OS in patients with a methylated MGMT promoter whether they received radiotherapy alone or chemotherapy (temozolomide or PCV) alone as the initial treatment [3 ] . Similarly, an analysis of tumor samples from the EORTC trial 26951 in MGMT promoter methylation was prognostic for PFS in both arms, that is, radiotherapy alone and radiotherapy followed by PCV [31 ] . The high correlation of MGMT promoter methylation with the 1p/19q codeletion [3 ,32] , which is a known favorable prognostic factor in anaplastic glioma [1, 2, 3 ], indicates a distinct pathogenetic context of the epigenetic deregulation of MGMT in anaplastic gliomas. There is emerging evidence, for example, in anaplastic gliomas that the relevance of MGMT promoter methylation may extend beyond the prediction of chemosensitivity, signifying a distinct molecular profile. MGMT promoter methylation may be predictive for the response to alkylating chemotherapy in glioblastoma but is mainly prognostic or predictive for both radiotherapy and chemotherapy in anaplastic gliomas [3 ,31 ] . Ongoing research aims at providing the data for a 'methylator' (with methylated MGMT) versus a nonmethylator (with unmethylated) MGMT anaplastic glioma subtype. Emerging molecular parameters call for a ranking amongst these prognosticators. In the NOA-04 trial, IDH-1 was more important than MGMT and histology, allowing a pure anaplastic astrocytoma with IDH1 mutation the same prognosis as an anaplastic oligodendroglioma/oligoastrocytoma with the alteration. Similarly, an anaplastic astrocytoma with IDH1 mutation had a much better prognosis than anaplastic oligodendroglioma/AOA without this mutation ([3 ] and unpublished data). In a nutshell and somewhat oversimplifying, a wish to a good fairy in neuropathology could be either an IDH1 mutation or MGMT promoter methylation or with somewhat lesser impact on the presence or absence of an unequivocal oligodendroglial component.
Developing new standards for newly diagnosed and recurrent disease
Neurooncologists have to face the fact that two large randomized trials failed to improve OS with therapy intensification even in oligodendroglial tumors, which had previously been regarded specifically as therapysensitive, but may in fact be insensitive, although prognostically better.
Improving radiotherapy or chemotherapy
The notion of relative chemosensitivity comes from the fact that 1p/19q-deleted tumors showed a trend towards better PFS when treated with PCV in addition to radiotherapy in the EORTC 26951 and RTOG 94-02 trials [1, 2, 36 ]. Further, the analysis of an old trial, EORTC 26882, on the addition of dibromodulcitol and bichloroethylnitrosourea to radiotherapy in anaplastic astrocytoma also suggested a trend for improved PFS and OS in the chemotherapy arm [37 ] . In contrast, glioblastoma patients obviously benefit from therapy intensification both postsurgically at diagnosis [6, 27, 38 ] and at recurrence [39, 40] . Looking at objective response rates [41] even complicates the picture, as glioblastoma rarely responds, and neither in glioblastoma nor in anaplastic glioma, response seems to predict survival [42] .
The precise determinators of sensitivity to genotoxic therapy remain obscure. The molecular explanation for
the greater sensitivity of 1p/19q-codeleted tumors could, in part, be explained by more frequent MGMT promoter gene methylation. Other hints may be found in the data from glioma-initiating cells that display a differential therapeutic sensitivity compared with the tumor bulk and potentially are located in a protected niche. Therefore, treatment intensification per se might be of limited value for anaplastic gliomas with a good prognosis, which is conferred by a mutated IDH1 gene, a methylated MGMT promoter or a diagnosis of an oligodendroglial tumor, whereas the other cohort might benefit from a treatment approach similar to glioblastoma with the emphasis on the concomitant chemoradiotherapy. However, there are concerns regarding late neurotoxicity related to the administration of concurrent chemoradiotherapy, manifesting itself particularly as cognitive decline as seen in patients with primary central nervous system (CNS) lymphoma [43] . For glioblastoma patients, this is probably not a major concern, as few patients will live long enough to experience late toxicity. However, this could be a real concern for anaplastic astrocytoma patients who may potentially live for several years with adverse effects of treatment that would substantially impact on the quality of the additional time they may gain from combined modality treatment. This concern is another argument for opting in worse prognosis patients and an argument for using temozolomide, which may be safely applied over several years [44 ] .
What is the role of molecularly defined therapies?
Molecularly targeted therapies may theoretically be more effective and less toxic than traditional cytotoxic chemotherapy. Results of the first targeted therapy trials for malignant gliomas have been disappointing. Although inhibiting vascular endothelial growth factor (VEGF) in recurrent glioblastoma with a humanized antibody, bevacizumab, holds some promise [45, 46 ] , other singleagent drugs have been largely unsuccessful when tested in recurrent disease in (controlled) clinical trials. These single agents included epidermal growth factor receptor (EGFR) inhibitors (gefitinib and erlotinib), the plateletderived growth factor receptor inhibitor imatinib, inhibitors of mammalian target of rapamycin, temsirolimus and everolimus, as well as protein kinase C-b and other angiogenesis pathway inhibitors such as vatalanib and enzastaurin [47 ,48 ] or most recently, the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) in a mono-compound recurrence trial in anaplastic astrocytoma [49 ] .
Similar to recurrent glioblastoma, a phase II trial in recurrent anaplastic gliomas demonstrated interesting activity of two bevacizumab (10 mg/kg every 14 days or 15 mg/kg every 3 weeks) and irinotecan (every 14 days or on days 1, 8, 22 and 29 every 6 weeks) regimens. The response rate was remarkable (61% partial responses according to [41] ), and the PFS at 6 months was high with 55% [50 ] . Given that it is difficult to find more impressive data in the literature, it is hard to understand that a randomized trial -minimizing selection biases per se -is missing, and that the role of irinotecan obviously needs to be redefined in anaplastic glioma after limited activity was demonstrated in glioblastoma [46 ] .
Nonetheless, as most of these trials have been done in glioblastoma and with single compounds, the role of these treatments in the different subgroups of anaplastic gliomas needs to be analyzed. These tumors may serve as excellent paradigms to test the activity of new compounds and combinations due to a slower course of disease and possibly a different biology, at least in the anaplastic oligodendroglioma/AOA subgroup. More specifically, immune-modulatory approaches involving antitransforming growth factor b strategies and vaccination that rely on minimal residual tumor burden as well as on the interval necessary to generate an immune response and therapies that aim at interfering with the dedifferentiation that occurs with the malignant transformation in most grade III tumors are prime candidates for being tested in anaplastic gliomas.
Conclusion
IDH1-mutated [51 ] or MGMT-methylated or oligodendroglial or 1p/19q-codeleted (better prognosis) anaplastic tumors are rare, diffusely infiltrating neoplasias, arising in the white matter of the cerebral hemispheres and displaying a better prognosis and possibly sensitivity to treatment than other anaplastic gliomas. There are no known predictive factors to stratify for specific treatments, and even the MGMT status is purely prognostic and not, as in glioblastoma, predictive for alkylating agent chemotherapy.
Treatment of choice of all anaplastic gliomas consists of resection as extensive and as well tolerated possible, followed by radiotherapy. These gliomas preferentially should be treated within clinical trials aiming at defining the role for concomitant radiochemotherapy with temozolomide or evaluating novel compounds. Outside trials, these tumors can be focally irradiated or treated with standard temozolomide or other alkylating agents, especially lomustine and procarbazine. Treatment choice at recurrence depends on prior therapy, duration of remission and availability of trials with antiangiogenic, antiinvasive, differentiating or immune-modulatory compounds. Future research will define the differential biology of the better prognosis anaplastic tumors.
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